Zenas BioPharma, Inc.
ZBIO
$32.53
-$0.52-1.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.62% | 66.32% | -366.89% | 1.39% | -55.55% |
| Total Depreciation and Amortization | -33.33% | -40.00% | -9.09% | -8.33% | -47.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 198.94% | -91.29% | 1,181.12% | 164.16% | -0.88% |
| Change in Net Operating Assets | 175.48% | -218.59% | 326.94% | -171.04% | 158.23% |
| Cash from Operations | 23.88% | -43.47% | -27.45% | 1.48% | -12.66% |
| Capital Expenditure | 100.00% | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,010.08% | 133.86% | -333.16% | 135.66% | -30.18% |
| Cash from Investing | -1,010.14% | 133.86% | -333.16% | 135.66% | -30.16% |
| Total Debt Issued | -89.12% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -91.05% | 10.86% | 15,877.02% | -45.41% | 1,639.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -280.66% | 94.52% | -113.03% | -- | -- |
| Cash from Financing | -90.30% | 207.77% | 93.96% | 4,116.96% | 1,639.39% |
| Foreign Exchange rate Adjustments | -145.34% | -2,927.27% | -56.00% | 110.59% | -353.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.94% | 8,011.92% | -106.88% | 146.91% | -23.74% |